Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2016

01-02-2016 | Review Article

Twist as a new prognostic marker in hematological malignancies

Authors: F. Norozi, A. Ahmadzadeh, M. Shahjahani, S. Shahrabi, N. Saki

Published in: Clinical and Translational Oncology | Issue 2/2016

Login to get access

Abstract

Twist proteins are members of basic helix-loop-helix family and are major regulators of embryogenesis. In adult humans, Twist proteins are mainly expressed in precursor cells, including myogenic, osteoblastic, chondroblastic and myelomonocytic lineages, maintaining their undifferentiated state. In addition, they play important roles in lymphocyte function and maturation. Recently, several studies have reported regulatory roles for Twist in the function and development of hematopoietic cells as well as in survival and development of numerous hematological malignancies. It is activated by numerous signal transduction pathways, including Akt, nuclear factor κB, Wnt, signal transducer and activator of transcription 3, mitogen-activated protein kinase and Ras signaling. Activated Twist has an anti-apoptotic role and protects cancer cells from apoptotic cell death. In addition, overexpression of Twist promotes the process of epithelial-mesenchymal transition, which has an essential role in cancer metastasis. Hereby, we review the aberrant expression of Twist in hematopoietic malignancies such as leukemias, lymphomas and myelodysplastic syndrome, which is related with poor prognosis and drug resistance in these disorders. Inactivation of Twist by small RNAs technology or chemotherapeutic inhibitors targeting Twist and upstream or downstream molecules of Twist signaling pathways may be helpful in management of disease to improve treatment strategies in malignancies.
Literature
1.
Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu H-H, Montagna MK, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. 2013;32(1):39–49.PubMedCentralPubMedCrossRef
2.
Kress W, Schropp C, Lieb G, Petersen B, Büsse-Ratzka M, Kunz J, et al. Saethre-Chotzen syndrome caused by TWIST1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. Eur J Hum Genet. 2006;14(1):39–48.PubMed
3.
Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X. Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer. 2007;120(9):1891–8.PubMedCrossRef
4.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.PubMedCrossRef
5.
Niitsu N, Okamoto M, Aoki S, Okumura H, Yoshino T, Miura I, et al. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol. 2006;85(6):374–80.PubMedCrossRef
6.
Khan MA. Chen H-c, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumor Biol. 2013;34(5):2497–506.CrossRef
7.
Cheng GZ, Zhang W, Sun M, Wang Q, Coppola D, Mansour M, et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 2008;283(21):14665–73.PubMedCentralPubMedCrossRef
8.
Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003;63(8):1906–13.PubMed
9.
10.
Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood. 2000;95(10):3208–13.PubMed
11.
Hosokawa K, Arai F, Yoshihara H, Iwasaki H, Nakamura Y, Gomei Y, et al. Knockdown of N-cadherin suppresses the long-term engraftment of hematopoietic stem cells. Blood. 2010;116(4):554–63.PubMedCrossRef
12.
Hosokawa K, Arai F, Yoshihara H, Iwasaki H, Hembree M, Yin T, et al. Cadherin-based adhesion is a potential target for niche manipulation to protect hematopoietic stem cells in adult bone marrow. Cell Stem Cell. 2010;6(3):194–8.PubMedCrossRef
13.
Yuen H-F, Kwok W-K, Chan K-K, Chua C-W, Chan Y-P, Chu Y-Y, et al. TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis. 2008;29(8):1509–18.PubMedCrossRef
14.
Bastid J, Ciancia C, Puisieux A, Ansieau S. Role of TWIST proteins in cancer progression. Atlas; 2009.
15.
Pang K, Ryan JF, Mullikin JC, Baxevanis AD, Martindale MQ. Genomic insights into Wnt signaling in an early diverging metazoan, the ctenophore Mnemiopsis leidyi. EvoDevo. 2010;1(1):10.PubMedCentralPubMedCrossRef
16.
Zhu D-Y, Guo Q-S, Li Y-L, Cui B, Guo J, Liu J-X, et al. Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression. World J gastroenterol: WJG. 2014;20(48):18306.PubMedCentralPubMedCrossRef
17.
Merindol N, Riquet A, Szablewski V, Eliaou J, Puisieux A, Bonnefoy N. The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. Blood Cancer J. 2014;4(4):e206.PubMedCentralPubMedCrossRef
18.
Barker N. The canonical Wnt/β-catenin signalling pathway. Wnt Signaling: Springer; 2008. p. 5–15.
19.
Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011;43(10):964–8.PubMedCentralPubMedCrossRef
20.
Schugar R, Robbins P, Deasy B. Small molecules in stem cell self-renewal and differentiation. Gene Ther. 2008;15(2):126–35.PubMedCrossRef
21.
Ansieau S, Bastid J, Doreau A, Morel A-P, Bouchet BP, Thomas C, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008;14(1):79–89.PubMedCrossRef
22.
Franco HL, Casasnovas J, Rodríguez-Medina JR, Cadilla CL. Redundant or separate entities? roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res. 2011;39(4):1177–86.PubMedCentralPubMedCrossRef
23.
Shahrabi S, Azizidoost S, Shahjahani M, Rahim F, Ahmadzadeh A, Saki N. New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia. Tumor Biol. 2014;35(11):10627–33.CrossRef
24.
Chotinantakul K, Leeanansaksiri W. Hematopoietic stem cell development, niches, and signaling pathways. Bone marrow research. 2012;2012.
25.
26.
Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol. 2006;76:103–27.PubMedCrossRef
27.
28.
Wang SM, Coljee VW, Pignolo RJ, Rotenberg MO, Cristofalo VJ, Sierra F. Cloning of the human twist gene: its expression is retained in adult mesodermally-derived tissues. Gene. 1997;187(1):83–92.PubMedCrossRef
29.
Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, et al. Deregulation of TWIST-1 in the CD34 + compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood. 2011;117(5):1673–6.PubMedCrossRef
30.
Sharabi AB, Aldrich M, Sosic D, Olson EN, Friedman AD, Lee S-H, et al. Twist-2 controls myeloid lineage development and function. PLoS Biol. 2008;6(12):e316.PubMedCentralPubMedCrossRef
31.
Isenmann S, Arthur A, Zannettino AC, Turner JL, Shi S, Glackin CA, et al. TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells. 2009;27(10):2457–68.PubMedCrossRef
32.
Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res. 2006;66(4):2195–201.PubMedCrossRef
33.
Qiao M, Shapiro P, Kumar R, Passaniti A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem. 2004;279(41):42709–18.PubMedCrossRef
34.
Sánchez-Beato M, Sánchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101(4):1220–35.PubMedCrossRef
35.
Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, et al. A twist code determines the onset of osteoblast differentiation. Dev Cell. 2004;6(3):423–35.PubMedCrossRef
36.
Haupt S, Alsheich-Bartok O, Haupt Y. Clues from worms: a Slug at Puma promotes the survival of blood progenitors. Cell Death Differ. 2006;13(6):913–5.PubMedCrossRef
37.
Saki N, Abroun S, Hagh MF, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell Journal (Yakhteh). 2011;13(3):131.PubMedCentral
38.
Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–6.PubMedCrossRef
39.
Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU. 1 in the development of multiple hematopoietic lineages. Science. 1994;265(5178):1573–7.PubMedCrossRef
40.
Pevny L, Simon MC, Robertson E, Klein WH, Tsai S-F, D’Agati V, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. 1991.
41.
Hendriks RW, Nawijn MC, Engel JD, van Doorninck H, Grosveld F, Karis A. Expression of the transcription factor GATA-3 is required for the development of the earliest T cell progenitors and correlates with stages of cellular proliferation in the thymus. Eur J Immunol. 1999;29(6):1912–8.PubMedCrossRef
42.
Dong CY, Liu XY, Wang N, Wang LN, Yang BX, Ren Q, et al. Twist-1, a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development. Stem Cells. 2014;32(12):3173–82.PubMedCrossRef
43.
Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα. Immunity. 2004;21(6):853–63.PubMedCrossRef
44.
Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, et al. AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells. J Biol Chem. 2008;283(44):30045–56.PubMedCentralPubMedCrossRef
45.
Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685–97.PubMedCrossRef
46.
Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149–61.PubMedCrossRef
47.
Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101(11):4333–41.PubMedCrossRef
48.
Cortez M, Carmo LS, Rogero MM, Borelli P, Fock RA. A high-fat diet increases IL-1, IL-6, and TNF-α production by increasing NF-κB and attenuating PPAR-γ expression in bone marrow mesenchymal stem cells. Inflammation. 2013;36(2):379–86.PubMedCrossRef
49.
Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med. 2008;205(8):1889–901.PubMedCentralPubMedCrossRef
50.
Pham D, Walline CC, Hollister K, Dent AL, Blum JS, Firulli AB, et al. The transcription factor Twist1 limits T helper 17 and T follicular helper cell development by repressing the gene encoding the interleukin-6 receptor α chain. J Biol Chem. 2013;288(38):27423–33.PubMedCentralPubMedCrossRef
51.
Koh HS, Lee C, Lee KS, Park EJ, Seong RH, Hong S, et al. Twist2 regulates CD7 expression and galectin-1-induced apoptosis in mature T-cells. Mol Cells. 2009;28(6):553–8.PubMedCrossRef
52.
Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res. 2001;29(22):4598–606.PubMedCentralPubMedCrossRef
53.
54.
Campisi J. Aging, tumor suppression and cancer: high wire-act! Mech Ageing Dev. 2005;126(1):51–8.PubMedCrossRef
55.
56.
Wickremasinghe R, Prentice A, Steele A. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia. 2011;25(9):1400–7.PubMedCrossRef
57.
Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, et al. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene. 2008;27(42):5543–53.PubMedCrossRef
58.
Rossi D, Ciardullo C, Spina V, Gaidano G. Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunol Lett. 2013;155(1):51–5.PubMedCrossRef
59.
Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999;13(17):2207–17.PubMedCentralPubMedCrossRef
60.
Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci. 1988;85(5):1629–33.PubMedCentralPubMedCrossRef
61.
Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas A-C, Combaret V, et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 2004;6(6):625–30.PubMedCrossRef
62.
Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays. 2003;25(7):691–8.PubMedCrossRef
63.
Hanzawa K, Momose S, Higashi M, Tokuhira M, Watanabe R, Kajino K, et al. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leuk lymphoma. 2010;51(11):2054–62.PubMedCrossRef
64.
Kuwano M, Oda Y, Izumi H, Yang S-J, Uchiumi T, Iwamoto Y, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004;3(11):1485–92.PubMed
65.
Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008;68(1):98–105.PubMedCrossRef
66.
Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol. 2002;128(11):621–6.PubMedCrossRef
67.
Shiota M, Song Y, Yokomizo A, Kiyoshima K, Tada Y, Uchino H, et al. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box–binding protein 1, and E-cadherin regulation. Clin Cancer Res. 2010;16(23):5654–63.PubMedCrossRef
68.
Min Y, Eom J, Cheong J, Maeng H, Kim J, Jeung H, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003;17(5):995–7.PubMedCrossRef
69.
Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci. 2001;98(20):11598–603.PubMedCentralPubMedCrossRef
70.
Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.PubMedCrossRef
71.
Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, Van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63(9):2172–8.PubMed
72.
Martelli A, Nyåkern M, Tabellini G, Bortul R, Tazzari P, Evangelisti C, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006;20(6):911–28.PubMedCrossRef
73.
Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, et al. Targeting PI3 K/AKT/mTOR network for treatment of leukemia. Cellular and Molecular Life Sciences. 2015:1-11.
74.
Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Constitutive activation of PI3 K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3 K activation. Leukemia. 2004;18(8):1438–40.PubMedCrossRef
75.
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang L-H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67(5):1979–87.PubMedCrossRef
76.
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European leukemianet. Blood. 2010;115(3):453–74.PubMedCrossRef
77.
Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(1):89–99.PubMedCrossRef
78.
Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC. Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res. 2007;67(22):10677–85.PubMedCrossRef
79.
Panju AH, Danesh A, Minden MD, Kelvin DJ, Alibhai SM. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer. 2009;17(5):539–46.PubMedCrossRef
80.
Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañas H, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61(3):885–91.PubMedCrossRef
81.
Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, et al. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children’s Oncology Group report. Blood. 2013;121(7):1083–93.PubMedCentralPubMedCrossRef
82.
Röhrs S, Scherr M, Romani J, Zaborski M, Drexler HG, Quentmeier H. Research CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. 2010.
83.
Venditti A, Poeta GD, Buccisano F, Tamburini A, Cox-Froncillo M, Aronica G, et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia. 1998;12(7):1056–63.PubMedCrossRef
84.
Saki N, Abroun S, Soleimani M, Mortazavi Y, Kaviani S, Arefian E. The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts. Hematology. 2014;19(3):141–7.PubMedCrossRef
85.
Li X, Marcondes AM, Gooley TA, Deeg HJ. The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood. 2010;116(13):2304–14.PubMedCentralPubMedCrossRef
86.
Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi N, Radich JP, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol. 2008;140(4):444–53.PubMedCrossRef
87.
88.
Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol. 1996;63(4):265–78.PubMedCrossRef
89.
Li X, Bryant E, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol. 2004;80(2):140–5.PubMedCrossRef
90.
Azizidoost S, Babashah S, Rahim F, Shahjahani M, Saki N. Bone marrow neoplastic niche in leukemia. Hematology. 2014;19(4):232–8.PubMedCrossRef
91.
Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579–87.PubMedCrossRef
92.
Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28(4):648–54.PubMedCentralPubMedCrossRef
93.
Galván JA, Helbling M, Koelzer VH, Tschan MP, Berger MD, Hädrich M, et al. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 2014.
94.
Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, et al. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica. 2012;97(3):371–8.PubMedCentralPubMedCrossRef
95.
San Jose-Eneriz E, Agirre X, Rodríguez-Otero P, Prosper F. Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia. Epigenomics. 2013;5(5):525–38.PubMedCrossRef
96.
Shahjahani M, Mohammadiasl J, Noroozi F, Seghatoleslami M, Shahrabi S, Saba F, et al. Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. Cell Oncol 2015;1–17.
97.
98.
Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer genetics. 2013;206(3):49–62.PubMedCrossRef
99.
Rosén A, Murray F, Evaldsson C, Rosenquist R, editors. Antigens in chronic lymphocytic leukemia—implications for cell origin and leukemogenesis. Semin Cancer Biol; 2010; Elsevier.
100.
Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005;23(17):3877–85.PubMedCrossRef
101.
Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46(1):95–106.PubMedCrossRef
102.
103.
Eriksen K, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15(5):787–93.PubMedCrossRef
104.
Izban KF, Ergin M, Qin J-Z, Martinez RL, Pooley RJ, Saeed S, et al. Constitutive expression of NF-κB is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol. 2000;31(12):1482–90.PubMedCrossRef
105.
Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci. 1994;91(13):6002–6.PubMedCentralPubMedCrossRef
106.
van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res. 2004;64(16):5578–86.PubMedCrossRef
107.
Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med. 1997;185(10):1851–8.PubMedCentralPubMedCrossRef
108.
Vespa GN, Lewis LA, Kozak KR, Moran M, Nguyen JT, Baum LG, et al. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol. 1999;162(2):799–806.PubMed
109.
Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. Cutting edge: CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol. 2000;165(5):2331–4.PubMedCrossRef
110.
Liu TY, Chen CY, Tien HF, Lin CW. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology. 2009;54(2):214–20.PubMedCrossRef
111.
Zhang J, Wang P, Wu F, Li M, Sharon D, Ingham RJ, et al. Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012;24(4):852–8.PubMedCrossRef
112.
Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci. 2009;100(2):233–7.CrossRef
113.
Montserrat N, Gallardo A, Escuin D, Catasus L, Prat J, Gutiérrez-Avignó FJ, et al. Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? Hum Pathol. 2011;42(1):103–10.PubMedCrossRef
114.
Inoue A, Seidel MG, Wu W, Kamizono S, Ferrando AA, Bronson RT, et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell. 2002;2(4):279–88.PubMedCrossRef
115.
Mancini M, Petta S, Iacobucci I, Salvestrini V, Barbieri E, Santucci MA. Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. Cell Signal. 2010;22(8):1247–53.PubMedCrossRef
116.
Lemma S, Karihtala P, Haapasaari KM, Jantunen E, Soini Y, Bloigu R, et al. Biological roles and prognostic values of the epithelial–mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology. 2013;62(2):326–33.PubMedCrossRef
117.
Xu W, Zhou L, Qin R, Tang H, Shen H. Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur J Haematol. 2009;83(4):313–9.PubMedCrossRef
118.
Rad SMAH, Bavarsad MS, Arefian E, Jaseb K, Shahjahani M, Saki N. The role of microRNAs in stemness of cancer stem cells. Oncol Rev. 2013;7(1):8.CrossRef
119.
Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci. 2010;107(32):14229–34.PubMedCentralPubMedCrossRef
120.
Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010;20(5):589–99.PubMedCentralPubMedCrossRef
121.
Li X, Xu F, Chang C, Byon J, Papayannopoulou T, Deeg HJ, et al. Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica. 2013;98(3):414–9.PubMedCentralPubMedCrossRef
122.
Lee Y-B, Bantounas I, Lee D-Y, Phylactou L, Caldwell MA, Uney JB. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res. 2009;37(1):123–8.PubMedCentralPubMedCrossRef
123.
Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro-oncology. 2011;13(10):1090–8.PubMedCentralPubMedCrossRef
124.
Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paíno T, et al. Restoration of miR-214 expression reduces growth of myeloma cells through a positive regulation of P53 and inhibition of DNA replication. Haematologica 2012.070011.
125.
Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 2012;279(13):2393–8.PubMedCrossRef
126.
Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451(7182):1125–9.PubMedCrossRef
127.
Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T. Complexity of miR-223 regulation by CEBPA in human AML. Leuk Res. 2010;34(5):672–6.PubMedCrossRef
128.
Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. Cell. 2005;123(5):819–31.PubMedCrossRef
129.
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011;9(7):824–33.PubMedCrossRef
130.
Eyholzer M, Schmid S, Wilkens L, Mueller B, Pabst T. The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer. 2010;103(2):275–84.PubMedCentralPubMedCrossRef
131.
132.
Li Y, Wang H, Tao K, Xiao Q, Huang Z, Zhong L, et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res. 2013;319(8):1094–101.PubMedCrossRef
133.
Park S-Y, Lee JH, Ha M, Nam J-W, Kim VN. miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nat Struct Mol Biol. 2009;16(1):23–9.PubMedCrossRef
134.
Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial–mesenchymal transition signaling. Mol Cancer Ther. 2012;11(5):1166–73.PubMedCrossRef
135.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2007;129(4):43–55.
Metadata
Title
Twist as a new prognostic marker in hematological malignancies
Authors
F. Norozi
A. Ahmadzadeh
M. Shahjahani
S. Shahrabi
N. Saki
Publication date
01-02-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1357-0

Other articles of this Issue 2/2016

Clinical and Translational Oncology 2/2016 Go to the issue

Research Article

Targeting thiamine-dependent enzymes for metabolic therapies in oral squamous cell carcinoma?

Research Article

Yes-associated protein (YAP) expression is involved in epithelial–mesenchymal transition in hepatocellular carcinoma

Research Article

A cross-sectional assessment of quality of life of colorectal cancer patients in Saudi Arabia

Research Article

VEGFR2 inhibition by RNA interference affects cell proliferation, migration, invasion, and response to radiation in Calu-1 cells

Research Article

Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma

Research Article

The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits